Compared with equal-dosage metformin monotherapy, the initial combination of metformin and DPP-IV inhibitors were more effective in glycemic control without additional risk of adverse events, therefore it can be considered as a beneficial therapeutic regimen for drug-naïve type 2 diabetes patients (Diabetes, Obesity and Metabolism)